Although previous studies had shown that TSA could increase the expression of the MSTN antagonist, follistatin [18,19], Benny-Klimek et al. found that treatment of tumour-bearing mice with TSA could not prevent muscle loss even at doses capable of inducing muscle growth in normal mice. Here, MSTN is linked to neoplasm.